The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X

Allergy

Volumn 48, Issue 5, 1993, Pages 377-382

  Pedersen, B ^a   Dahl, R ^a   Larsen, B B ^a   Venge, P ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

allergen challenge; bronchial reactivity; eosinophil cationic protein; eosinophil protein X; eosinophils; salmeterol

Indexed keywords

ALLERGEN; BRONCHODILATING AGENT; HISTAMINE; SALMETEROL;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL ARTICLE; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ALLERGENS; ASTHMA; BLOOD PROTEINS; BRONCHIAL PROVOCATION TESTS; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HISTAMINE; HUMAN; LEUKOCYTE COUNT; MALE;

EID: 0027200678     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1993.tb02410.x     Document Type: Article

References (31)

1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
2. Salmeterol, a novel, long‐acting beta‐2‐adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo
3. Eosinophil inflammation in asthma
4. Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung
5. Bronchial reactivity to inhaled histamine: a method and clinical survey
6. Allergen‐induced increase in non‐allergic bronchial reactivity
7. Blood eosinophil count and eosinophil cationic protein. In vivo study of the influence of beta‐2‐adrenergic drugs and steroid medication
8. Variation of blood eosinophils and eosinophil cationic protein in serum in patients with bronchial asthma: studies during inhalation challenge test
9. Bronchoalveolar eosinophils during allergen‐induced late asthmatic reaction
10. Blood eosinophils and eosinophil derived proteins in allergic asthma
11. Antiasthma drugs attenuate inflammatory leakage into airway lumen
12. European Community for Coal and Steel. Report of Working Party. Standardization of lung‐function tests
13. The appearance of hypodense eosinophils in antigen‐dependent late phase asthma
14. Blood eosinophil number and activity in relation to lung function in patients with asthma and with eosinophilia
15. The effect of submucosal edema on airways resistance
16. Influence of albuterol, cromolyn sodium, and ipratropium bromide on the airway and circulating mediator responses to antigen bronchial provocation in asthma
17. The pharmacology of salmeterol
18. Beta‐adrenergic blockade and circulating eosinophils
19. Bronchial challenge: a small reservoir for the Wright jet nebulizer
20. Bronchoalveolar lavage of allergic asthma patients following allergen bronchoprovocation
21. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs: description of the model and local airway in flammation
22. Immunopathology of allergic lung disease
23. Purification and characterization of a new cationic protein – eosinophil protein‐X (EPX)‐ from human eosinophils
24. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen allergic patients
25. Physiology and pharmacodynamics of beta‐adrenergic agonists
26. Protection against allergen‐induced asthma by salmeterol
27. Are blood eosinophil number and activity important for the development of the late asthmatic reaction after allergen challenge
28. Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effect of anti‐asthma medication
29. Eosinophils in exerciseinduced asthma
30. Radioimmunoassay of human eosinophil cationic protein
31. 2‐adrenergic receptors on eosinophils. Bindings and functional studies